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ABSTRACT
In this study,we identified twopreviouslydescribedkinase inhibitors—
3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(3-methyl-1H-pyrazol-
5-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine
(LY2784544) and 1H-benzimidazole-4-carboxylic acid, 2-methyl-
1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-
(GSK2636771)—as novel GPR39 agonists by unbiased
small-molecule-based screening using a b-arrestin recruit-
ment screening approach (PRESTO-Tango).We characterized the
signaling of LY2784544 and GSK2636771 and compared their
signaling patterns with a previously described “GPR39-selective”
agonist N-[3-chloro-4-[[[2-(methylamino)-6-(2-pyridinyl)-4-
pyrimidinyl]amino]methyl]phenyl]methanesulfonamide (GPR39-C3)
at both canonical and noncanonical signaling pathways. Unex-
pectedly, all three compounds displayed probe-dependent and
pathway-dependent allosteric modulation by concentrations
of zinc reported to be physiologic. LY2784544 and GS2636771 at
GPR39 in the presence of zinc were generally as potent or more
potent than their reported activities against kinases in whole-cell
assays. These findings reveal an unexpected role of zinc as an
allosteric potentiator of small-molecule-induced activation of
GPR39 and expand the list of potential kinase off-targets to
include understudied G protein–coupled receptors.
Introduction
G protein–coupled receptors (GPCRs) transduce extracellu-
lar stimuli into intracellular signals, have crucial roles in
virtually all of human physiology, and are the targets for about
one-third of currently marketed drugs (Overington et al., 2006;
Rask-Andersen et al., 2014). When agonists bind to GPCRs,
signals are transduced into cells via a number of Ga proteins,
or b-arrestins, and other interacting proteins. In the human
genome, there are about 350 nonolfactory GPCRs, of which
about 100 are still orphans, i.e., their endogenous ligands are yet
unknown (Vassilatis et al., 2003; Fredriksson and Schiöth, 2005;
Bjarnadóttir et al., 2006; Regard et al., 2008; Komatsu et al.,
2014; Roth and Kroeze, 2015), or alternatively, they are very
poorly annotated with respect to ligands, whether endogenous
or surrogate. In the current study, we report on the discovery of
novel surrogate ligands for GPR39, previously described as a
zinc receptor (Holst et al., 2007).
GPR39 is a member of the ghrelin peptide receptor family.
Although the ligands of the nonorphan receptors in this family
are all peptides [ghrelin, growth hormone secretagogue receptor
(Kojima et al., 1999); neurotensin, NTSR1 and NTSR2 (Tanaka
et al., 1990; Vita et al., 1998); motilin, MLNR (Feighner et al.,
1999); neuromedin U, NMUR1 and NMUR2 (Kojima et al.,
2000; Bhattacharyya et al., 2004)], GPR39 has been reported to
be a Zn21metal ion–sensing receptor (Holst et al., 2007). Other
divalent metal ions, such as Ni21, Cd21, Cr21, and Fe21, have
also been reported to activate GPR39 (Holst et al., 2007; Huang
et al., 2015). GPR39 is widely expressed in several organs,
including the gastrointestinal tract, pancreas, thyroid, brain,
and others (Popovics and Stewart, 2011).
GPR39 has been reported to be associated with type 2 di-
abetes (Holst et al., 2009; Verhulst et al., 2011) and depression
(Młyniec and Nowak, 2015; Młyniec et al., 2015a,b,c). GPR39
has been found to be expressed in mouse intestinal fibroblast-
like cells (Zeng et al., 2012), human colon adenocarcinoma
HT-29 cells (Yasuda et al., 2007; Cohen et al., 2012, 2014), rat
colon BRIN-BD11 cells (Moran et al., 2016), and mouse
pancreatic epithelial NIT-1 cells (Fjellström et al., 2015). All of
these cell types respond to Zn21 via various signal transduction
pathways. Early studies reported the peptide obestatin to be a
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ABBREVIATIONS: AZ1395, 3,4-bis-(2-imidazol-1-ylethoxy)-benzonitrile; AZ4237, 6-[(4-chlorophenyl)methyl]-7-hydroxy-5-methyl-pyrazolo[1,5-a]
pyrimidine-3-carboxylic acid; AZ7914, 6-(3-chloro-2-fluoro-benzoyl)-2-(2-methylthiazol-4-yl)-3,5,7,8-tetrahydropyrido-[4,3-d]pyrimidin-4-one;
DMEM, Dulbecco’s modified Eagle’s medium; FBS, fetal bovine serum; GPCR, G protein–coupled receptor; GPR39-C3, N-[3-chloro-4-
[[[2-(methylamino)-6-(2-pyridinyl)-4- pyrimidinyl]amino]methyl]phenyl]methanesulfonamide; GSK2636771, 1H-benzimidazole-4-carboxylic acid,
2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-; HBSS, Hanks’ balanced salt solution; HEK293T, human embryonic
kidney 293T; HTLA, HEK293-derived cell line containing stable integrations of a tetracycline transactivator–dependent luciferase reporter and a
b-arrestin2–tobacco etch virus fusion gene; IBMX, 3-isobutyl-1-methylxanthine; LY2784544, 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(3-methyl-
1H-pyrazol-5-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine; PAM, positive allosteric modulator; PBS, phosphate-buffered saline;
PTEN, phosphatase and tensin homolog deleted from chromosome 10; RLU, relative luminescence units.
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GPR39 agonist (Zhang et al., 2005), but subsequent work failed
to reproduce these results (Lauwers et al., 2006; Holst et al.,
2007; Zhang et al., 2007). Zn21 stimulates signaling via the Gq
andb-arrestin pathways, aswell as theGspathway (Holst et al.,
2007). Recently, three groups reported small-molecule agonists
for GPR39 (Boehm et al., 2013; Peukert et al., 2014; Fjellström
et al., 2015). However, the signaling pathways induced by these
agonists, and their relationship to Zn21 concentrations, remain to
be elucidated. Additionally, the physiologic significance of each
GPR39 signaling pathway remains unclear. Here, we provide an
approach for discovering new GPR39 agonists useful for illumi-
nating GPR39 signaling pathways. We exemplify two compounds
and elucidate how their signaling is allosterically modulated by
Zn21.
Materials and Methods
Compounds. The following libraries were screened in quadrupli-
cate using a modified TANGO b-arrestin recruitment assay (Barnea
et al., 2008; Kroeze et al., 2015) for activity at GPR39: NCC-1
(446 compounds; National Clinical Collection), NIMH X-901 (271 com-
pounds; National Institute of Health Clinical Collection, Bethesda, MD),
Prestwick (1120 compounds; Illkirch, France), Tocris (1280 compounds;
Bristol, UK), Selleckchem (1836 compounds; Munich, Germany), and
Spectrum (2400 compounds; MicroSource, Gaylordsville, CT) at a drug
concentration of 10 mM to which transfected cells was exposed, following
the previously publishedmethod (Kroeze et al., 2015). Daughter libraries
were prepared and kept at220°C until use. 3-(4-Chloro-2-fluorobenzyl)-
2-methyl-N-(3-methyl-1H-pyrazol-5-yl)-8-(morpholinomethyl)imidazo
[1,2-b]pyridazin-6-amine (LY2784544), 1H-benzimidazole-4-carboxylic
acid, 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-
morpholinyl)-(GSK2636771), N-[3-chloro-4-[[[2-(methylamino)-6-(2-
pyridinyl)-4- pyrimidinyl]amino]methyl]phenyl]methanesulfonamide
(GPR39-C3), and obestatin were obtained from Selleckchem, MedChem
Express (Monmouth Junction, NJ), Xcessbio (San Diego, CA), and
Sigma-Aldrich (St. Louis, MO), respectively.
Site-Directed Mutagenesis. The His17Ala/His19Ala mutation
in GPR39was introduced using the GPR39-TANGO construct (Kroeze
et al., 2015) as a template, PrimeSTAR Max (TAKARA Clontech,
Mountain View, CA) as the polymerase, and the following primers:
39T-H17AH19A_S: 59- GACGCTAGCGCTGTGCCGGAGTTTGAAG-
TGGC -39, 39T-H17AH19A_A: 59- CACAGCGCTAGCGTCAA-
TAATCTGGCTACAGT-39. Mutations were confirmed by sequencing
(Eton Bioscience Inc., Research Triangle Park, NC). For assess-
ment of G protein–mediated signaling, GPR39-TANGO con-
structs were “de-TANGO-ized” by introduction of a stop codon
Fig. 1. Summary of drug screening at GPR39
using the TANGO b-arrestin recruitment assay. (A)
Screening was carried out in quadruplicate at 10 mM
drug concentration. After excluding promiscuous
activators, LY2784544 and GSK2636771 were iden-
tified as GPR39-selective agonists for the b-arrestin
pathway (B and C). (B) Structures of LY2784544
(middle) and GSK2636771 (right) and a previously
described GPR39 (left) agonist, GPR39-C3. (C) Activ-
ities of LY2784544 and GSK2636771 at GPR39 and
11 additional understudied GPCRs.
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immediately following the GPR39 open reading frame using the
primers TangoUniStopCleanF (59-GACGCACCTAGCTCGAGTCTA-
GAGGGCCCG-39) and TangoUniStopCleanR (59-CTCGAGC-
TAGGTGCGTCCACCGGTATCGAT-39), and confirmed by sequencing.
TANGO Assay. HTLA cells [a human embryonic kidney
293 (HEK293) cell line stably expressing a tetracycline transactivator–
dependent luciferase reporter and a b-arrestin2–tobacco etch virus
fusion gene] were a gift from the laboratory of R. Axel (Columbia
University, New York, NY) and were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum
(FBS), 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mg/ml puromycin,
and 100 mg/ml hygromycin B in a humidified atmosphere at 37°C in 5%
CO2. TANGOb-arrestin recruitment assayswere carried out as described
byKroeze et al. (2015). All experiments were performed in quadruplicate.
Results expressed as relative luminescence units (RLU) were exported
into Excel spreadsheets (Microsoft, Redmond, WA), and analyses were
done using GraphPad Prism (GraphPad Software, La Jolla, CA). To
calculate fold change, wells without compounds and without Zn21 were
used as “basal”; results were finally expressed as log2-fold change.
PRESTO-Tango GPCR-ome Profiling. The PRESTO-Tango
GPCR-ome assay was performed as previously described (Kroeze
et al., 2015). HTLA cells were cultured in poly-L-Lys–coated 384-well
white clear-bottom cell culture plates (Greiner, Monroe, NC) in
DMEM supplemented with 10% dialyzed FBS at a density of 10,000
cells/well in a total volume of 50 ml 1 day before transfection. The next
day, 40 ng/well DNA was transfected into each well using the calcium
phosphate precipitation method. The following day, the medium was
aspirated from the plate and replaced with 50 ml/well fresh DMEM
containing 1% dialyzed FBS and 100 mM ZnCl2, with or without 1 mM
compound, and incubated overnight. DRD2 and 1 mM quinpirole were
set on every plate as a positive control for this assay. The detection
step was performed using the method described by Kroeze et al.
(2015). All experimentswere done in quadruplicate. Results expressed
as RLU were exported into Excel spreadsheets, and analyses were
done using GraphPad Prism. The mean fold change for each receptor
was calculated as (mean RLUwith ligand/mean RLUwithout ligand).
Inositol Phosphate Accumulation Assay. Inositol phosphate
accumulation assays were performed as in previous reports (https://
pdspdb.unc.edu/pdspWeb/content/PDSP%20Protocols%20II%202013-03-
28.pdf; Storjohann et al., 2008). HEK293T cells were maintained in
DMEM supplemented with 10% FBS, 100 U/ml penicillin, and
100 mg/ml streptomycin. Cells were transfected with 20 mg of receptor
DNA per 15-cm cell-culture dish and incubated overnight at 37°C in a
humidified 5% CO2 incubator. The next day, 30,000 cells/well were
seeded into poly-L-lysine–coated 96-well plates in 100 ml/well DMEM
supplemented with 10% dialyzed FBS, 100 U/ml penicillin, and
100 mg/ml streptomycin. After attaching to the plate, cells were
incubated for 16 hours as described earlier in inositol-free DMEM
(United States Biological, Salem, MA) containing 10% dialyzed FBS
and 1 mCi/well of myo-[3H]inositol (PerkinElmer, Waltham, MA). On
the following day, cells were washed with 100 ml of drug buffer [1
Hanks’ balanced salt solution (HBSS), 24 mM NaHCO3, 11 mM
glucose, and 15 mM LiCl, pH 7.4] and treated with 100 ml of drug
buffer containing drug and 0.3% bovine serum albumin (Sigma-
Aldrich) in quadruplicate for 1 hour at 37°C in a 5% CO2 incubator.
After treatment, drug solutionwas removed by aspiration, and 40ml of
50 mM formic acid was added to lyse cells for 30 minutes at 4°C. After
cell lysis, 20 ml of the acid extract was transferred to each well of a
polyethylene terephthalate96-well sampleplate (1450-401;PerkinElmer)
and mixed with 75 ml of PerkinElmer RNA Binding YSi SPA Beads
(RPNQ0013) at a concentration of 0.2 mg beads/well and incubated for
30 minutes at room temperature. Bead/lysate mixtures were then
counted with a Microbeta Trilux counter (Perkin-Elmer, Boston, MA).
Data were exported into Excel spreadsheets and analyzed using
GraphPad Prism.
cAMP Accumulation Assay. Receptor-mediated Gs pathway sig-
naling was measured using a split-luciferase receptor assay (GloSensor
cAMP assay; Promega, Madison, WI). In brief, HEK293T cells were
transiently cotransfected with receptor DNA and the GloSensor cAMP
reporter plasmid (GloSensor 7A). The following day, transfected cells
were plated into poly-L-lysine–coated 384-well white clear-bottom cell
culture plates in DMEM supplemented with 1% dialyzed FBS (Omega
Scientific, Tarzana, CA), 100 U/ml penicillin, and 100 mg/ml streptomy-
cin at a density of 15,000 cells/well in a total volume of 40 ml. The next
day, culture medium was removed by aspiration, and cells were
incubatedwith 20ml of 4mM luciferin (GoldBio, St. Louis,MO) prepared
in drug buffer (20 mM HEPES, 1 HBSS, and 0.3% bovine serum
albumin, pH 7.4) for 30minutes at 37°C. Next, cells were incubated with
10 ml of a 3 concentration of drug at room temperature for 15 minutes.
Following drug treatment, cells were incubated with 10 ml of a
4 concentration of ZnCl2 solution in drug buffer, or drug buffer alone,
for 15 minutes at room temperature. Luminescence was then counted
using a Microbeta Trilux luminescence counter (PerkinElmer). All
experiments were performed in quadruplicate and exported into Excel
spreadsheets, which were then analyzed using GraphPad Prism. To
calculate fold change, wells without compounds and without Zn21 were
used as “basal.”
Cell Enzyme-Linked Immunosorbent Assay. To confirm cell
surface expression of the FLAG-tagged GPR39 and its mutants,
immunohistochemistry was done using cells plated into 384-well
plates, as described earlier, at 10,000 cells/well. Cells were fixed with
20 ml/well 4% paraformaldehyde for 10 minutes at room temperature.
After fixation, cells were washed twice with 40 ml/well of phosphate-
buffered saline (PBS) at pH 7.4. Blocking was done with 20 ml/well 5%
normal goat serum in PBS for 30 minutes at room temperature. After
Fig. 2. GPCR-ome (PRESTO-Tango) analysis of three compounds:
GPR39-C3 (A), LY2784544 (B), and GSK2636771 (C). These assays were
performed using 1 mM concentrations of each compound with 100 mM
ZnCl2. The results are the mean 6 S.E.M. of quadruplicate determina-
tions. The right-most bar (PC) represents the positive control, which was
the DRD2 dopamine receptor stimulated with 1 micromolar of the agonist
quinpirole.
728 Sato et al.
blocking, 20 ml/well anti-FLAG–horseradish peroxidase–conjugated
antibody (Sigma-Aldrich) diluted 1/10,000 was added and incubated
for 1 hour at room temperature. This was followed by two washes with
80 ml/well PBS. Then, 20 ml/well SuperSignal Enzyme-Linked Immu-
nosorbent Assay Pico Substrate (Sigma-Aldrich) was added, and
luminescence was counted using a MicroBeta Trilux luminescence
counter. Expression of mutants was normalized by using expression
of wild-type receptors as 100% and untransfected cells as 0%. As
previously stated, all experiments were done in quadruplicate.
Fluorescent Imaging Plate Reader Assay. HT-29 (ATCC) and
PC-3 (obtained from Kim Laboratory, The Lineberger Comprehensive
Cancer Center, University of North Carolina, Chapel Hill) were
maintained in 10% FBS, McCoy’s 5A medium (Gibco, Thermo Fisher
Scientific, Waltham, MA) plus 10% FBS, and DMEM plus 10% FBS,
respectively. The cells were seeded into poly-L-Lys–coated 384-well black
clear-bottom cell culture plates in each medium supplemented with 10%
dialyzed fetal bovine serumatadensity of 10,000cells/well ina total volume
of 50 ml 1 day before assay. The following day, mediumwas discarded, and
cells were loaded with 20 ml/well of 1 Fluo-4 Direct Calcium dye (20 mM
HEPES, 1 HBSS, 2.5 mM probenecid, pH 7.40) (Thermo Fisher
Scientific). Plates were incubated for 60 minutes at 37°C. The
fluorescent imaging plate reader was programmed to take 10 readings
(1 read per second) first as a baseline before addition of 10 ml of 3
drug solutions. The fluorescence intensity was recorded for 2 minutes
after drug addition.
Results
Discovery of Novel GPR39 Agonists. The TANGO
b-arrestin recruitment assay was used to screen several
compound libraries (Materials and Methods), totaling
Fig. 3. Concentration-dependent and GPR39-dependent b-arrestin recruitment as measured by the TANGO assay in response to GPR39-C3 (A),
LY2784544 (B), or GSK2636771 (C) in the presence of various concentrations of Zn2+. (D) Zn2+ stimulations were carried out at several different
incubation times with Zn2+ from 5 minutes to 6 hours, followed by washing and incubation with fresh medium or overnight incubation with Zn2+. The
results are expressed as the fold of basal and are the mean 6 S.E.M. of three independent experiments, each performed in quadruplicate.
TABLE 1
Pharmacological parameters of results shown in Fig. 3, A–C
Top and bottom are expressed as fold of basal, and log EC50 is expressed as logged EC50 (M).
ZnCl2
316 mM (N = 3) 100 mM (N = 8) 31.6 mM (N = 3) 10 mM (N = 3) 3.2 mM (N = 3) 0 mM (N = 8)
GPR39-C3
Top 0.04 6 0.00 30.27 6 0.57 22.03 6 0.71 23.23 6 0.88 26.81 6 1.92 33.25 6 2.31
Bottom 0.01 6 0.00 1.09 6 0.36 0.98 6 0.21 0.99 6 0.20 0.95 6 0.19 1.00 6 0.16
Log EC50 28.63 6 0.17 27.99 6 0.04 27.09 6 0.06 26.72 6 0.06 26.40 6 0.11 26.22 6 0.11
Hill slope 0.82 6 0.24 1.52 6 0.17 0.79 6 0.07 0.83 6 0.08 0.72 6 0.07 0.69 6 0.05
LY2784544
Top 0.03 6 0.00 23.16 6 0.52 11.38 6 0.45 7.99 6 0.33 6.59 6 0.51 7.10 6 0.78
Bottom 0.01 6 0.00 0.89 6 0.25 1.02 6 0.12 0.97 6 0.06 0.92 6 0.05 1.00 6 0.03
Log EC50 28.93 6 0.27 28.17 6 0.04 26.86 6 0.06 26.26 6 0.04 26.03 6 0.07 25.81 6 0.11
Hill slope 1.10 6 0.66 1.45 6 0.15 1.28 6 0.17 1.61 6 0.20 1.51 6 0.25 1.27 6 0.16
GSK2636771
Top 0.03 6 0.00 22.56 6 0.59 22.96 6 3.48 10.84 6 0.99 .153.7 .73.15
Bottom 0.00 6 0.00 0.83 6 0.21 1.05 6 0.16 0.99 6 0.04 0.97 6 0.05 1.00 6 0.03
Log EC50 27.96 6 0.29 27.07 6 0.04 25.42 6 0.16 25.31 6 0.07 .-4.07 .-4.25
Hill slope 0.64 6 0.25 1.18 6 0.11 1.04 6 0.17 1.66 6 0.21 1.50 6 1.02 1.59 6 0.86
Novel Agonists of the GPR39 Zinc Receptor 729
approximately 5000 unique compounds, for agonist activity at
GPR39 in the absence of Zn21. Approximately 20 compounds
showed activities over 2-fold higher than basal (i.e., log2-fold
change . 1) (Fig. 1A); after exclusion of promiscuous com-
pounds that also activated other GPCR targets (data not
shown), the JAK2 inhibitor LY2784544 and the PI3Kb in-
hibitor GSK2636771 were identified as GPR39 agonists (Fig.
1A). The structures of these compounds are similar to each
other, but are markedly different from the GPR39-C3 com-
pound that has previously been reported to be an agonist at
GPR39 (Fig. 1B; Peukert et al., 2014). When tested at 11 other
GPCRs, neither of these compounds showed agonist activity
(Fig. 1C). Additionally, we also tested obestatin, which has
previously been reported to be a GPR39 agonist (Zhang et al.,
2005), for activity at GPR39 and found it to be inactive
(Supplemental Fig. 1A); we then tested obestatin for activity
at 320 GPCRs using the PRESTO-Tango method (Kroeze
et al., 2015; Manglik et al., 2016) and found it to be inactive at
all targets tested (Supplemental Fig. 1B), both in the presence
and absence of Zn21. Additionally, we performed a GPCR-ome
analysis (Kroeze et al., 2015; Manglik et al., 2016) for all three
GPR39 agonist compounds, i.e., GPR39-C3, LY2784544, and
GSK2636771. At 1 mM concentrations, and in the presence of
100 mMZnCl2, each compound showed obvious activity at only
one receptor in addition to GPR39: HTR1A by GPR39-C3,
MTLNR1A by LY2784544, and CXCR7 by GSK2636771,
respectively (Fig. 2, A–C). Thus, these compounds are highly
specific agonists at GPR39. These activities were subse-
quently confirmed with concentration-response curves (Sup-
plemental Fig. 2).
AllostericModulation of GPR39b-ArrestinRecruitment
Activity. Since Zn21 had previously been reported to be an
agonist at GPR39, and because it seemed unlikely that these
compounds might be interacting at the zinc site, we wondered
if zinc allosterically modulated the GPR39 agonist activity of
small molecules. We used the previously reported GPR39
Fig. 4. Concentration-dependent and GPR39-dependent phosphatidylinositol hydrolysis (Gq pathway) in response to GPR39-C3 (A), LY2784544 (B),
or GSK2636771 (C) with various concentrations of Zn2+. According to an allosteric operational model, the allosteric parameters were calculated
(Kenakin, 2012). tA is the orthosteric agonist (LY2784544 and GSK2636771) efficacy parameter. Since allosteric modulators in this study showed
agonist activity, the allosteric modulator efficacy (tB) is therefore greater than 0. Concentration-dependent and GPR39-dependent PI hydrolysis (Gq
pathway) in response to ZnCl2 (D), NiCl2 (E), and NiSO4 (F). Black dots show response to compounds in untransfected HEK293T cells. The results are
the mean 6 S.E.M. of at least three independent experiments performed in quadruplicate (compounds and ZnCl2) or duplicate (NiCl2).
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agonist GPR39-C3 (Peukert et al., 2014), as well as the two
compounds discovered in our screens, LY2784544 and
GSK2636771 (Fig. 1), at various concentrations of Zn21 in the
TANGO assay (Fig. 3). Zn21 alone showed very little activity in
this assay (Fig. 3D). However, all three compounds showed a
Zn21-dependent increase in potency and efficacy up to a Zn21
concentration of 100 mM (Fig. 3, A–C); at a Zn21 concentration
of 316 mM, no activity was seen, presumably due to the toxic
effects of Zn21 at such high concentrations. In an attempt to
determine whether responses to Zn21 could be seenwith shorter
exposures to its potentially toxic effects, we exposed GPR39-
expressing HTLA cells to Zn21 for various times, followed by a
washout, and continued incubation overnight; longer exposures
to higher concentrations of Zn21 were apparently toxic to cells,
but significant b-arrestin recruitment activity was not seen at
any concentration, or with any length of exposure (Fig. 3D). The
efficacy and potency values for these three compounds at various
Zn21 concentrations are shown in Table 1; all three compounds
showed Emax values between 20- and 30-fold above basal at
100 mMZn21. Interestingly, GPR39-C3 showed marked activity
in the absence of Zn21, whereas LY2784544 and GSK2636771
hadminimal or noactivity in the absence of zinc. Taken together,
the results shown in Table 1 indicate that Zn21 acts as a positive
allosteric modulator (PAM) of the activity of GPR39-C3 in terms
of efficacy only, whereas Zn21 was a PAM for the activities of
LY2784544 and GSK2636771 in terms of both efficacy and
potency. It should be noted that all three compounds were
apparently toxic to HTLA cells at high concentrations, and
therefore, data from these high concentrations were excluded
from this analysis. We also tested whether LY2784544 could act
as an antagonist to the GPR39-C3 response at various Zn21
concentrations, and found that LY2784544 did not antagonize
the GPR39-C3 response (Supplemental Fig. 3). Together, our
results suggest that Zn21 stabilizes a conformation of GPR39
that can be further activated to recruitb-arrestin byLY2784544.
In addition, Ni21 was also shown to be an agonist of GPR39 in
b-arrestin recruitment activity (Fig. 4), as had previously been
reported using a bioluminescence resonance energy transfer
assay (Holst et al., 2007).
Allosteric Modulation of GPR39 Gq-Mediated
Signaling. We also measured GPR39-mediated Gq pathway
signaling using a phosphatidylinositol hydrolysis assay. As
can be seen in Fig. 4, A–C, all three tested compounds
stimulated Gq signaling. The Zn21 dependence of responses
to LY2784544 (Fig. 4B) and GSK2636771 (Fig. 4C) was much
greater than that of GPR39-C3 (Fig. 4A), with leftward shifts
of more than 1000-fold compared with less than 10-fold for
GPR39-C3. At the higher Zn21 concentrations, all three
compounds were much more potent with respect to Gq
signaling (Fig. 4, A–C) than they were in b-arrestin re-
cruitment (Fig. 3), showing EC50 values in the low nanomolar
range (Table 2). The allosteric parameters were calculated
according to the Black-Leff Ehlert model (Kenakin, 2012).
The allosteric modulator efficacy values (tB) were greater
than 0, indicating that Zn21 is a PAM agonist (Fig. 4, B and
C). All three compounds showed a maximal efficacy of 3- to
4-fold over basal (Table 2). The maximal efficacy of all three
compounds at GPR39 in Gq signaling was not affected by
Zn21 concentration (Fig. 4, A–C; Table 2), although Zn21 and
Ni21 stimulated GPR39-mediated Gq signaling on their own
(Fig. 4, D–F; Table 3). Interestingly, the potency of Ni21 was
slightly higher than that of Zn21. All of these divalent metal
ions showed steep Hill slopes (.2.5) (Table 3), which we
interpret to mean that divalent metal ions can act as their
own PAMs at GPR39. The concentrations at which Zn21 was
active in this assay, i.e., in the high micromolar range, were
comparable to those seen in vivo (Foster et al., 1993; Caroli
et al., 1994; Lu et al., 2012). Zinc has been estimated at 200–
320 mM in vivo in hippocampus mossy fibers (GPR39 is
enriched in the hippocampus) (Frederickson et al., 1983) and
at levels .100 mM during synaptic transmission (Assaf and
Chung, 1984). The concentrations we used in our experi-
ments (3.4–340 mM) are in this range. Taken together, these
TABLE 2
Pharmacological parameters of results shown in Fig. 3, A–C
Top and bottom are expressed as fold of basal, and log EC50 is expressed as logged EC50 (M).
ZnCl2
316 mM (N = 4) 100 mM (N = 4) 31.6 mM (N = 4) 0 mM (N = 4)
GPR39-C3
Top 2.59 6 0.06 3.21 6 0.08 2.87 6 0.08 3.07 6 0.10
Bottom 1.40 6 0.09 1.18 6 0.11 0.96 6 0.10 1.00 6 0.10
Log EC50 28.49 6 0.13 28.48 6 0.10 28.16 6 0.11 28.00 6 0.12
Hill slope 1.29 6 0.46 1.20 6 0.30 1.18 6 0.30 0.94 6 0.23
LY2784544
Top 3.40 6 0.38 3.94 6 0.30 4.57 6 0.12 4.41 6 0.07
Bottom 1.92 6 0.07 1.31 6 0.11 1.07 6 0.22 1.00 6 0.22
Log EC50 29.36 6 0.14 28.51 6 0.14 26.98 6 0.16 26.35 6 0.19
Hill slope 1.30 6 0.18 0.63 6 0.17 0.79 6 0.15 0.94 6 0.59
GSK2636771
Top 3.47 6 0.09 3.68 6 0.12 3.75 6 0.27 3.68 6 0.63
Bottom 1.91 6 0.15 1.36 6 0.12 1.08 6 0.08 1.01 6 0.05
Log EC50 28.60 6 0.18 27.97 6 0.13 26.67 6 0.14 25.99 6 0.25
Hill slope 1.01 6 0.38 0.86 6 0.20 1.01 6 0.25 1.01 6 0.28
TABLE 3
Pharmacological parameters of results shown in Fig. 4, D–F
Top and bottom are expressed as fold of basal, and log EC50 is expressed as logged
EC50 (M).
ZnCl2 (N = 3) NiCl2 (N = 3) NiSO4 (N = 3)
Top 2.19 6 0.06 2.20 6 0.08 2.58 6 0.10
Bottom 1.00 6 0.03 0.98 6 0.04 1.00 6 0.05
Log EC50 24.09 6 0.05 24.73 6 0.07 24.88 6 0.08
Hill slope 3.23 6 1.40 2.53 6 0.67 3.46 6 1.95
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results led to the conclusion that GPR39-C3, LY2784544,
GSK2636771, Zn21, and Ni21 can all act as agonists of
GPR39-mediated Gq signaling, and that Zn21 is a PAM of
the responses of GPR39-C3, LY2784544 and GSK2636771.
Allosteric Modulation of GPR39 Gs-Mediated
Signaling. In addition, wemeasured GPR39-mediated Gs path-
way signaling (i.e., cAMP production) as described (seeMaterials
and Methods). All three tested compounds, i.e., GPR39-C3,
Fig. 5. Concentration-dependent and GPR39-dependent cAMP (Gs) responses, as measured by the Glosensor assay, to GPR39-C3 (A), LY2784544 (B), or
GSK2636771 (C) with various concentrations of Zn2+. Responses in the absence of Zn2+ are shown in (D), (E), and (F). Responses to ZnCl2, NiCl2, and NiSO4 are
shown in (G) and (H) and (I), respectively. The results are the mean 6 S.E.M. of at least three independent experiments performed in quadruplicate.
TABLE 4
Pharmacological parameters of the results shown in Fig. 4, A–C
Top and bottom are expressed as fold of basal, and log EC50 is expressed as logged EC50 (M).
ZnCl2
316 mM (N = 3) 100 mM(N = 13)
31.6 mM
(N = 3)
10 mM
(N = 3)
3.16 mM
(N = 3)
0 mM
(N = 13)
GPR39-C3
Top 22.76 6 0.89 7.68 6 0.15 3.18 6 0.13 N.D. N.D. N.D.
Bottom 2.33 6 0.24 1.38 6 0.05 1.29 6 0.04 N.D. N.D. N.D.
Log EC50 27.05 6 0.07 26.72 6 0.04 26.17 6 0.08 N.D. N.D. N.D.
Hill slope 0.87 6 0.10 1.01 6 0.08 1.70 6 0.45 N.D. N.D. N.D.
LY2784544
Top 18.86 6 0.38 7.24 6 0.19 1.96 6 0.07 N.D. N.D. N.D.
Bottom 2.04 6 0.21 1.20 6 0.10 1.12 6 0.03 N.D. N.D. N.D.
Log EC50 27.75 6 0.05 27.37 6 0.08 26.47 6 0.08 N.D. N.D. N.D.
Hill slope 1.14 6 0.12 1.13 6 0.37 3.31 6 3.73 N.D. N.D. N.D.
GSK2636771
Top 16.41 6 0.51 4.80 6 0.12 N.D. N.D. N.D. N.D.
Bottom 1.93 6 0.18 1.10 6 0.05 N.D. N.D. N.D. N.D.
Log EC50 27.12 6 0.06 27.09 6 0.05 N.D. N.D. N.D. N.D.
Hill slope 1.10 6 0.14 1.29 6 0.17 N.D. N.D. N.D. N.D.
N.D., could not determine.
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LY2784544, andGSK2636771, showed Zn21-dependentGs signal-
ing (Fig. 5, A–C; Table 4). Importantly, even GPR39-C3 showed a
dramatic Zn21dependency of this response, despite not doing so in
eitherb-arrestin recruitment (Fig. 3A) orGq signaling (Fig. 4A). In
untransfected cells, or in the absence of Zn21, neither of the
compounds showed GPR39-mediated Gs pathway signaling (Fig.
5, D–F). At high concentrations, i.e., 30 mM and higher, Zn21 and
Ni21 also acted as weak partial agonists of GPR39-mediated Gs
pathway signaling (Fig. 5, G–I; Table 5). Thus, GPR39-C3,
LY2784544, GSK2636771, Zn21, and Ni21 can all act as agonists
of GPR39-mediated Gs signaling, and additionally, Zn21 is a PAM
for the Gs-mediated responses of GPR39-C3, LY2784544, and
GSK2636771.
Effects of Mutation of N-Terminal Histidine Residues
on GPR39-Mediated Signaling. A previous study showed
that mutation of two N-terminal histidine residues to alanine
(H17A/H19A) in GPR39 led to a dysfunction in GPR39-mediated
Gq signaling (Storjohann et al., 2008) such that Zn21-stimulated
signaling was completely abolished. We wished to study the
effects of these mutations further with respect to both various
signaling pathways and various agonists and PAMs. First,
using cell enzyme-linked immunosorbent assay, we estab-
lished that the H17A/H19A double mutant of GPR39 was
expressed similarly to thewild-typeGPR39, both in theTANGO
constructs as well as the “de-TANGO-ized” constructs (Supple-
mental Fig. 4). In Fig. 6 and Table 6, it can be seen that the
H17A/H19A double mutant of GPR39 had little effect on
b-arrestin recruitment activity in response to both the three
small-molecule compounds of interest, as well as the activity
of Zn21 as a PAM of these responses. The double mutation
completely abolished Gq signaling stimulated by either Zn21 or
Ni21 (Fig. 7, D–F), consistent with the report by Storjohann
et al. (2008). The double mutation had little or no effect on Gq
signaling stimulated byGPR39-C3, LY2784544, orGSK2636771
in either the presence or absence of 100 mM Zn21 (Fig. 7, A–C;
Table 7). As with Gq signaling, the double mutation com-
pletely abolished Gs signaling stimulated by either Zn21 or
Ni21 (Fig. 8, D–F). However, the double mutant showed re-
duced Gs signaling stimulated by GPR39-C3, LY2784544,
or GSK2636771 with respect to both potency and efficacy (Fig. 8,
A–C; Table 8).
Discussion
Here, we report the discovery of novel GPR39 agonist
scaffolds and the identification of zinc as a GPR39 PAM. These
are the first results to identify zinc as a potent and frequently
pathway- and probe-specific allosteric modulator for small-
molecule GPR39 agonists. To discover these GPR39 agonists,
we used a b-arrestin recruitment assay to screen several
compound libraries comprising more than 5000 unique
compounds for agonist activity at the orphan GPCR GPR39,
which had previously been reported to be a divalent metal ion
zinc receptor. Two compounds were found that had selective
activity at GPR39—the JAK2 inhibitor LY2784544 and the
PI3Kb inhibitor GSK2636771 (Figs. 1 and 2). In additional
studies, we showed that Zn21 is an allosteric modulator of the
responses of GPR39 to LY2784544 and GSK2636771, and that
the allosteric actions of Zn21 on these responses were stronger
than for the selective GPR39 agonist, GPR39-C3 (Fig. 3).
Currently, LY2784544 is being evaluated in patients with
myeloproliferative neoplasm in two phase I trials to investigate
dose and schedule (I3X-MC-JHTA, NCT01134120; and I3X-
MC-JHTC, NCT01520220) and a phase II study to investigate
efficacy (I3X-MC-JHTB, NCT01594723) (Ma et al., 2013).
Additionally, GSK2636771 is being tested in a phase I/II trial
in patients with phosphatase and tensin homolog (PTEN)–
deficient advanced solid tumors (NCT01458067) (Thorpe et al.,
2015). Indeed, when the potencies for activating GPR39 in the
presence of Zn21 were calculated, we found their EC50 values
TABLE 5
Pharmacological parameters of results shown in Fig. 5, G–I
The results are the mean 6 S.E.M. of five independent experiments performed in
quadruplicate. Top and bottom are expressed as fold of basal, and log EC50 is
expressed as logged EC50 (M).
ZnCl2 (N = 7) NiCl2 (N = 5) NiSO4 (N = 5)
Top 4.22 6 0.20 2.99 6 0.07 3.24 6 0.12
Bottom 0.95 6 0.02 0.93 6 0.02 0.92 6 0.02
Log EC50 23.42 6 0.04 24.04 6 0.04 23.91 6 0.06
Hill slope 2.62 6 0.57 1.75 6 0.24 1.25 6 0.16
Fig. 6. Concentration-dependent b-arrestin recruitment responses of
wild-type (WT) and H17A/H19A mutant receptors to GPR39-C3 (A),
LY2784544 (B), and GSK2636771 (C) in the presence and absence of
100 mM Zn2+ as measured by the TANGO assay. The results are the
mean 6 S.E.M. of at least five independent experiments, each done in
quadruplicate.
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were in the sub- to single-digit nanomolar range in whole-cell
assays. By comparison, the potency of LY2784544 in whole-cell
assays for inhibition of JAK2proliferationwas 20 nM (Ma et al.,
2013), whereas GSK2636771 had a potency of 7–114 nM in
whole-cell assays (Qu et al., 2015). These results indicate that,
in terms of the cellular context, the activities at GPR39 could
predominate.
Given that these compounds are being tested in clinical trials,
it should be of interest to establish whether they activate off-
targets. Also, if side effects of these compoundsare found, itmay
be possible to link the side effects to the off-targets rather than
the targets and, thus, to provide clues as to the physiologic
function(s) of orphan off-targets. In a clinical study of
LY2784544, diarrhea, nausea, anemia, and transient increases
in serum creatinine, uric acid, and potassium have been
reported and attributed to a “typical tumor lysis syndrome”
(Tefferi, 2012); however, it seems conceivable that at least some
of these effects might be due to activation of GPR39. In-
terestingly, GPR39 is highly expressed in human colorectal
adenocarcinoma HT-29 cells, and Zn21 and a GPR39 agonist
stimulated Gq signaling and promoted survival in these cells
(Cohen et al., 2012, 2014; Boehm et al., 2013). By using the
fluorescent imaging plate reader assay, we have shown that
GPR39-C3, LY2784544, and GSK2636771 strongly activate the
Gq pathway in HT-29 cells (Supplemental Fig. 5). Since
LY2784544 shows modulator activity in the presence of
physiologic concentrations of Zn21, it will be important to
determine in clinical trials whether its side effects are due to
its activity at GPR39.
Moreover, Zn21 induced increased cell growth and survival
in GPR39-expressing human prostate cancer PC-3 cells (Dubi
et al., 2008; Asraf et al., 2014). Importantly, prostate tissue is
rich in Zn21 (Györkey et al., 1967; Zaichick et al., 1997). In the
absence of Zn21, the selective PI3Kb inhibitor GSK2636771
TABLE 6
Pharmacological parameters of results shown in Fig. 6
Top and bottom are expressed as fold of basal, and log EC50 is expressed as logged EC50 (M).
WT H17A/H19A
ZnCl2 (+) (N = 8) ZnCl2 (2) (N = 8) ZnCl2 (+) (N = 5) ZnCl2 (2) (N = 5)
GPR39-C3
Top 30.27 6 0.57 33.25 6 2.31 25.87 6 0.55 29.07 6 2.02
Bottom 1.09 6 0.36 1.00 6 0.16 1.08 6 0.34 1.00 6 0.24
Log EC50 27.99 6 0.04 26.22 6 0.11 27.76 6 0.04 26.43 6 0.10
Hill slope 1.52 6 0.17 0.69 6 0.05 1.51 6 0.18 0.84 6 0.10
LY2784544
Top 23.16 6 0.52 7.10 6 0.78 19.26 6 0.56 7.23 6 0.97
Bottom 0.89 6 0.25 1.00 6 0.03 0.91 6 0.27 1.00 6 0.06
Log EC50 28.17 6 0.04 25.81 6 0.11 28.07 6 0.04 25.91 6 0.12
Hill slope 1.45 6 0.15 1.27 6 0.16 1.61 6 0.23 1.57 6 0.38
GSK2636771
Top 22.61 6 0.59 N.D. 22.85 6 0.93 N.D.
Bottom 0.831 6 0.21 1.00 6 0.03 0.91 6 0.27 1.00 6 0.07
Log EC50 27.068 6 0.04 .24.00 26.94 6 0.06 .24.00
Hill slope 1.179 6 0.11 1.59 6 0.86 1.05 6 0.13 1.703 6 0.75
N.D., could not determine; WT, wild type.
Fig. 7. Concentration-dependent phosphatidylinositol hydrolysis responses (Gq pathway) to GPR39-C3 (A), LY2784544 (B), and GSK2636771 (C) in the
presence and absence of 100 mM Zn2+ at wild-type (WT) and H17A/H19A mutant receptors. Concentration-dependent PI hydrolysis responses (Gq
pathway) to ZnCl2 (D), NiCl2 (E), or NiSO4 (F). The results are the mean6 S.E.M. of at least three independent experiments, each done in quadruplicate.
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significantly decreases cell viability in p110b-reliant PTEN-
deficient PC-3 cells (Weigelt et al., 2013). In the present
study, we discovered that GSK2636771 could promote
GPR39-selective intracellular signaling, which was markedly
enhanced by the divalent metal ion Zn21 (Figs. 3–5). Addi-
tionally, we have confirmed GPR39- and Gq-mediated Ca21
release in PC-3 cells after stimulation with GPR39 ago-
nists in the presence of Zn21 (Supplemental Fig. 6). Since
GSK2636771 has been developed as a potential treatment of
PTEN-deficient advanced solid tumors, including colorectal
cancer, it may be important to consider possible off-target
effects of this compound due to its actions at GPR39. In
addition, and more generally, our approach shows that new
activities for compounds and new modulators for poorly
annotated GPCRs can be discovered by screening modestly
sized libraries of already-known small molecules.
The divalent metal ion Zn21 has been reported to allosteri-
cally modulate GPCR function, not only GPR39 but also
5HT1A-serotonin (Barrondo and Sallés, 2009; Satała et al.,
2015), a(1A)-adrenoreceptor (Ciolek et al., 2011), and b2-
adrenergic receptor (Swaminath et al., 2002). Furthermore,
the divalent metal ion Zn21 can stimulate GPR68 (Abe-Ohya
et al., 2015) andGPRC6A (Pi andQuarles, 2012; Pi et al., 2012) in
the micromolar to millimolar range. Interestingly, Zn21 modu-
lates GPR39 activity via the Gq, Gs, and b-arrestin pathways
(Holst et al., 2007). Other divalent cations, including Ni21 (Holst
et al., 2007) and even Cr21, Fe21, and Cd21 (Huang et al., 2015),
can also activate GPR39. In general, most GPCRs can modulate
one G protein signaling pathway in addition to the b-arrestin
pathway, although there are many exceptions. Our data show
that LY2784544 and GSK2636771 can strongly stimulate Gq
(Fig. 4), Gs (Fig. 5), and b-arrestin (Fig. 3) pathways. However,
the mechanisms of stimulation of these compounds may not be
the same and may not be shared with Zn21 or GPR39-C3. For
example, the Zn21-dependent enhancement of potency in the
Gq and b-arrestin pathways induced by LY2784544 and
TABLE 7
Pharmacological parameters of results shown in Fig. 7
Top and bottom are expressed as fold of basal, and log EC50 is expressed as logged EC50 (M).
WT H17A/H19A
ZnCl2 (+) (N = 4) ZnCl2 (2) (N = 4) ZnCl2 (+) (N = 3) ZnCl2 (2) (N = 3)
GPR39-C3
Top 3.21 6 0.08 3.07 6 0.10 3.72 6 0.14 3.75 6 0.22
Bottom 1.18 6 0.11 1.00 6 0.10 1.07 6 0.17 1.03 6 0.11
Log EC50 28.48 6 0.10 28.00 6 0.12 28.30 6 0.14 27.17 6 0.14
Hill slope 1.20 6 0.30 0.94 6 0.23 1.01 6 0.29 0.90 6 0.23
LY2784544
Top 3.94 6 0.12 4.41 6 0.38 3.77 6 0.13 3.85 6 0.16
Bottom 1.31 6 0.22 1.00 6 0.07 1.09 6 0.27 1.03 6 0.04
Log EC50 28.51 6 0.16 26.35 6 0.14 28.72 6 0.18 26.23 6 0.07
Hill slope 0.63 6 0.15 0.94 6 0.18 0.88 6 0.29 1.15 6 0.15
GSK2636771
Top 3.68 6 0.12 3.68 6 0.63 3.74 6 0.12 3.00 6 0.11
Bottom 1.36 6 0.12 1.01 6 0.05 1.14 6 0.15 1.01 6 0.02
Log EC50 27.97 6 0.13 25.99 6 0.25 28.16 6 0.13 25.99 6 0.05
Hill slope 0.86 6 0.20 1.01 6 0.28 0.95 6 0.24 1.35 6 0.16
WT, wild type.
Fig. 8. Concentration-dependent cAMP production (Gs pathway) to GPR39-C3 (A), LY2784544 (B), and GSK2636771 (C) in the presence and absence of
100 mM Zn2+ at wild-type (WT) and H17A/H19A mutant receptors as measured by the Glosensor assay. Concentration-dependent cAMP production (Gs
pathway) to ZnCl2 (D), NiCl2 (E), or NiSO4 (F) at wild-type or H17A/H19A mutant receptors as measured by the Glosensor assay. The results are the
mean 6 S.E.M. of at least eight independent experiments, each in quadruplicate.
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GSK2636771, which have similar structures, is much greater
than that induced by GPR39-C3 (Figs. 3 and 4), although
clearly additional studies are needed to clarify the molecular
details responsible for these intriguing signaling differences.
The potency and efficacy of Zn21 alone in the b-arrestin
pathway are quite small (Fig. 3). In the TANGO assay, which
requires overnight incubation with ligand, the toxicity of high
concentrations of Zn21 prevented measurement of b-arrestin
recruitment at these concentrations.However, it has been shown
thatNi21 can stimulateb-arrestin recruitment toGPR39using a
bioluminescence resonance energy transfer assay (Holst et al.,
2007), and presumably, this would be similar to Zn21. In
comparison with the activities of GPR39-C3, LY2784544, and
GSK2636771, our results show that the responses to Zn21 alone
are quite small. We conclude that Zn21 acts as a small-molecule
PAM agonist at GPR39 for these two pathways.
Stimulation of the Gs (cAMP) pathway by compounds acting
at GPR39 followed a very different pattern when compared
with the Gq and b-arrestin pathways. The divalent cations
Zn21 and Ni21 stimulated this pathway on their own;
additionally, the GPR39-C3 compound, even without Zn21,
showed significant Gs activity (Fig. 5). This is in agreement
with a previous study (Peukert et al., 2014), which showed an
EC50 value of 60 nM and an efficacy of 64% of the activity
shown by 25 mM forskolin. Another study found that the
GPR39 agonists AZ1395, 3,4-bis-(2-imidazol-1-ylethoxy)-
benzonitrile; AZ4237, 6-[(4-chlorophenyl)methyl]-7-hydroxy-
5-methyl-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid; AZ7914,
6-(3-chloro-2-fluoro-benzoyl)-2-(2-methylthiazol-4-yl)-3,5,7,8-
tetrahydropyrido-[4,3-d]pyrimidin-4-one also stimulated cAMP
responses without Zn21 (Fjellström et al., 2015); however, the
phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine
(IBMX) was used in that study, which makes estimation of the
“true” pharmacological parameters of these compounds difficult.
Our results showed that all three compounds, i.e., GPR39-C3,
LY2784544, and GSK2636771, had similar and significant Zn21
dependency in their Gs responses, and were thus acting as PAM
agonists with respect to Zn21 in the Gs pathway.
The differences in the activities of the divalent cations and
GPR39-C3, LY2784544, and GSK2636771 at GPR39 suggest
that there may be multiple binding sites or modes for divalent
cations in GPR39. It has already been shown that two
histidine residues in the N terminus (H17 and H19) are
involved in Zn21 activity, since the Gq pathway response to
concentrations of Zn21 less than 1mM is completely abolished
by alanine substitution of these residues (Storjohann et al.,
2008). Our results confirm these observations, and the re-
sponse to Ni21 was also abolished by these mutations (Fig. 7).
Additionally, the Gs (cAMP) response to Zn21 was also
abolished by these mutations (Fig. 8). Thus, we conclude that
H17 and H19 form one binding site for Zn21 in GPR39.
However, the H17A/H19A double mutation did not affect the
activity of zinc or the zinc dependency of the activities of
GPR39-C3, LY2784544, and GSK2636771 in the Gq or
b-arrestin recruitment assays (Figs. 6 and 7). From this, we
conclude that there must be an additional zinc-binding site in
GPR39, that the zinc-binding sites act independently of each
other, and that the H17/H19 zinc-binding site is orthosteric,
whereas the yet-unknown additional site is allosteric.
In conclusion, here we report that the previously described
“selective” kinase inhibitors LY2784544 and GSK2636771
have unexpectedly selective PAMagonist activity with respect
to Zn21 at GPR39. All tested compounds induced Gq, Gs, and
b-arrestin signaling, and those responses are modulated by
the divalent metal ion Zn21 acting as a PAM agonist. We also
clarified the roles of key residues in GPR39 relating only to
divalent metal ion agonist activity by using mutagenesis.
Although several ligands for GPR39 have been reported,
whether there are endogenous ligands other than divalent
metal ions for GPR39 is still not clear. Additionally, the
physiologic functions of GPR39 signaling in vivo remain to
be determined, and the scaffolds described here may provide
starting points for novel chemical probes for GPR39.
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TABLE 8
Pharmacological parameters of the results shown in Fig. 8, A–C
The results are the mean 6 S.E.M. of least eight independent experiments, each in quadruplicate. Top and bottom are
expressed as fold of basal, and log EC50 is expressed as logged EC50 (M). The statistical significance of the difference in
values between the wild type (WT) and mutant was determined using a one-sided t test.
WT H17A/H19A
ZnCl2 (+) (N = 13) ZnCl2 (2) (N = 13) ZnCl2 (+) (N = 8) ZnCl2 (2) (N = 8)
GPR39-C3
Top 7.68 6 0.11 N.D. 6.01 6 0.13* N.D.
Bottom 1.38 6 0.17 N.D. 1.37 6 0.18 N.D.
Log EC50 26.72 6 0.10 N.D. 26.49 6 0.12* N.D.
Hill slope 1.01 6 0.37 N.D. 1.22 6 0.22 N.D.
LY2784544
Top 7.24 6 0.20 N.D. 4.86 6 0.13* N.D.
Bottom 1.20 6 0.06 N.D. 1.17 6 0.04 N.D.
Log EC50 27.37 6 0.05 N.D. 27.08 6 0.05* N.D.
Hill slope 1.13 6 0.12 N.D. 1.35 6 0.17 N.D.
GSK2636771
Top 4.80 6 0.12 N.D. 3.84 6 0.12* N.D.
Bottom 1.10 6 0.05 N.D. 1.06 6 0.03 N.D.
Log EC50 27.09 6 0.05 N.D. 26.46 6 0.06* N.D.
Hill slope 1.29 6 0.17 N.D. 1.20 6 0.16 N.D.
N.D., could not determine.
*p , 0.05.
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